FDA Rejects Chinese Lung Cancer Drug Ivonescimab; Overall Survival Data Falls Short
nashnova research
The FDA on November 15 refused to approve ivonescimab, a dual-target lung-cancer drug developed by China's Akeso Biopharma, because overall survival did not reach statistical significance in the pivotal trial. The rejection blocks — at least for now — what many saw as a flagship test of Chinese biotech's push into the U.S. market.
Where exactly did ivonescimab fall short?
The FDA set a clear bar: the drug must show a statistically significant improvement in overall survival (OS) — how long patients live from start of treatment. Ivonescimab slowed disease progression, but did not clear the "do patients live longer?" threshold.
Summit submitted post-hoc analyses with longer follow-up, arguing that death risk fell in both Western and Asian subgroups. But these analyses were not pre-specified in the trial protocol, and the FDA declined to accept them.
In plain terms = if the analysis was not written into the trial design upfront, presenting it after the fact as proof of efficacy does not pass regulatory scrutiny.
Why does this matter beyond one drug?
Ivonescimab was developed by Akeso Biopharma (億一生物) in China. Summit Therapeutics licensed the U.S. rights and filed for approval. The drug was widely viewed as a flagship product of China's biotech globalization push.
The FDA explicitly requested Western-population data during its review. This reflects a continuing regulatory caution about whether Chinese clinical trial results transfer directly to American patients.
This means → for every Chinese-origin drug company planning to enter the U.S. on the strength of China-run trials, this rejection sends a signal: Chinese data alone may not be enough.
What exactly is ivonescimab?
It is a bispecific antibody — a single drug hitting two targets at once — given by IV infusion. One arm activates the immune system against the tumor; the other blocks tumor blood-vessel growth, starving its blood supply.
Merck, Pfizer, and other major pharma companies are developing drugs with similar dual mechanisms. Supporters of ivonescimab had expected it to challenge or even replace the world's best-selling cancer drug — Merck's pembrolizumab (Keytruda).
Cancer researchers broadly agree that current clinical data does not yet support such a broad indication claim.
What comes next?
Ivonescimab has 17 late-stage clinical studies globally — ongoing, completed, or planned.
The most critical is a Phase III trial expected to read out by year-end: it enrolls previously untreated advanced lung-cancer patients and runs a head-to-head comparison against pembrolizumab on both overall survival and progression delay.
In plain terms = if that trial shows ivonescimab beats Keytruda on the "how long do patients live" metric, Summit has the most direct basis to refile with the FDA. If it does not, the drug's commercial outlook faces much deeper doubt.
市场有风险,内容仅供研究参考,不构成投资建议。
